Prime Medicine, Inc. (PRME) 10-Year Financial Performance & Capital Metrics

PRME • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $3M
EBITDA -$196M +1.9%
Net Income -$196M +1.1%
EPS (Diluted) -1.65 +24.2%
Gross Margin 100%
EBITDA Margin -6581.93%
Operating Margin -6787.36%
Net Margin -6566.61%
ROE -136.88% -55.2%
ROIC -260.47% -122.6%
Debt/Equity 0.27 +160.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 30.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM647.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM9.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM26.54%

ROCE

10Y Avg-75.21%

5Y Avg-58.98%

3Y Avg-76.44%

Latest-102%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	5.21M	0	0	0	2.98M
Revenue Growth %	-	-	-1%	-	-	-
Cost of Goods Sold+	2.76M	2.98M	0	0	0	0
COGS % of Revenue	-	0.57%	-	-	-	-
Gross Profit+	-2.76M	2.23M	0	0	0	2.98M
Gross Margin %	-	0.43%	-	-	-	1%
Gross Profit Growth %	-	1.81%	-1%	-	-	-
Operating Expenses+	2.17M	3.16M	84.47M	116.54M	204.79M	205.45M
OpEx % of Revenue	-	0.61%	-	-	-	68.87%
Selling, General & Admin	1.25M	3.16M	13.92M	29.82M	43.39M	50.16M
SG&A % of Revenue	-	0.61%	-	-	-	16.82%
Research & Development	920K	2.98M	70.55M	86.72M	147.91M	155.29M
R&D % of Revenue	-	0.57%	-	-	-	52.06%
Other Operating Expenses	0	-2.98M	0	0	13.5M	0
Operating Income+	-2.17M	-932K	-84.47M	-116.54M	-204.79M	-202.47M
Operating Margin %	-	-0.18%	-	-	-	-67.87%
Operating Income Growth %	-	0.57%	-89.64%	-0.38%	-0.76%	0.01%
EBITDA+	4.34M	-889K	-83.91M	-114.32M	-200.14M	-196.34M
EBITDA Margin %	-	-0.17%	-	-	-	-65.82%
EBITDA Growth %	-	-1.2%	-93.38%	-0.36%	-0.75%	0.02%
D&A (Non-Cash Add-back)	6.52M	43K	568K	2.22M	4.65M	6.13M
EBIT	-2.52M	-932K	-84.47M	-116.54M	-191.29M	-202.47M
Net Interest Income+	0	0	0	0	0	3.52M
Interest Income	0	0	0	0	0	3.52M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	0	-611K	-81.38M	-6.22M	6.38M	6.58M
Pretax Income+	-2.52M	-1.54M	-165.85M	-122.77M	-198.41M	-195.88M
Pretax Margin %	-	-0.3%	-	-	-	-65.67%
Income Tax+	4K	1.87M	-486K	-948K	-279K	0
Effective Tax Rate %	1%	2.21%	1%	0.99%	1%	1%
Net Income+	-2.53M	-3.41M	-165.37M	-121.82M	-198.13M	-195.88M
Net Margin %	-	-0.65%	-	-	-	-65.67%
Net Income Growth %	-	-0.35%	-47.49%	0.26%	-0.63%	0.01%
Net Income (Continuing)	-2.53M	-3.41M	-165.37M	-121.82M	-198.13M	-195.88M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.03	-0.05	-1.92	-1.46	-2.18	-1.65
EPS Growth %	-	-0.81%	-35.43%	0.24%	-0.49%	0.24%
EPS (Basic)	-0.03	-0.05	-1.92	-1.46	-2.18	-1.65
Diluted Shares Outstanding	95.73M	95.73M	95.73M	97.21M	90.97M	118.6M
Basic Shares Outstanding	95.73M	95.73M	95.73M	97.21M	90.97M	118.6M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.7M	53.4M	270.58M	296.62M	142.98M	211.89M
Cash & Short-Term Investments	8.65M	53.33M	269.62M	293.92M	121.67M	190.44M
Cash Only	8.65M	36.98M	185.42M	187.62M	41.57M	182.48M
Short-Term Investments	0	16.35M	84.2M	106.3M	80.09M	7.97M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	50K	0	0	246K	2.25M	14.67M
Total Non-Current Assets+	0	1.38M	31.28M	63.7M	50.88M	85.62M
Property, Plant & Equipment	0	596K	15.68M	48.55M	36.6M	71.56M
Fixed Asset Turnover	-	8.74x	-	-	-	0.04x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	785K	15.6M	15.14M	14.28M	14.06M
Total Assets+	8.7M	54.78M	301.86M	360.31M	193.85M	297.51M
Asset Turnover	-	0.10x	-	-	-	0.01x
Asset Growth %	-	5.3%	4.51%	0.19%	-0.46%	0.53%
Total Current Liabilities+	7.31M	19.44M	57.98M	26.71M	56.42M	37.96M
Accounts Payable	0	250K	1.44M	4.33M	19.54M	11.35M
Days Payables Outstanding	-	30.62	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K
Other Current Liabilities	7.31M	19.08M	14.66M	6.98M	10.91M	6.93M
Current Ratio	1.19x	2.75x	4.67x	11.10x	2.53x	5.58x
Quick Ratio	1.19x	2.75x	4.67x	11.10x	2.53x	5.58x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	1.87M	4.31M	17.33M	4.36M	106.4M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	3.07M	17.05M	4.36M	37.18M
Deferred Tax Liabilities	0	1.87M	1.24M	279K	0	0
Other Non-Current Liabilities	0	0	0	0	0	6M
Total Liabilities	7.31M	21.31M	62.3M	44.04M	60.78M	144.36M
Total Debt+	0	0	10.41M	28.75M	13.63M	40.79M
Net Debt	-8.65M	-36.98M	-175.01M	-158.88M	-27.94M	-141.68M
Debt / Equity	-	-	0.04x	0.09x	0.10x	0.27x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-1.99x	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	1.39M	33.47M	239.56M	316.27M	133.07M	153.15M
Equity Growth %	-	23.1%	6.16%	0.32%	-0.58%	0.15%
Book Value per Share	0.01	0.35	2.50	3.25	1.46	1.29
Total Shareholders' Equity	1.39M	33.47M	239.56M	316.27M	133.07M	153.15M
Common Stock	1K	0	0	2K	2K	2K
Retained Earnings	-2.6M	-6.01M	-171.38M	-293.2M	-491.33M	-687.21M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-27K	-384K	-15K	1K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.33M	-5.54M	-34.08M	-131.83M	-165.41M	-122.86M
Operating CF Margin %	-	-1.06%	-	-	-	-41.19%
Operating CF Growth %	-	-3.16%	-5.15%	-2.87%	-0.25%	0.26%
Net Income	-2.53M	-3.41M	-165.37M	-121.82M	-198.13M	-195.88M
Depreciation & Amortization	0	43K	568K	2.22M	4.65M	6.13M
Stock-Based Compensation	0	391K	1.75M	6.46M	13.91M	26.07M
Deferred Taxes	0	1.87M	-624K	-964K	-279K	0
Other Non-Cash Items	703K	-4.6M	98.42M	17.68M	11.79M	9.74M
Working Capital Changes	492K	164K	31.18M	-35.4M	2.65M	31.08M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	250K	1.19M	2.46M	9.14M	-5.26M
Cash from Investing+	0	-1.06M	-73.63M	-47.1M	18.71M	68.46M
Capital Expenditures	0	-639K	-4.15M	-16.09M	-8.72M	-7.29M
CapEx % of Revenue	-	0.12%	-	-	-	2.45%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	-423K	-496K	-665K	-170K	1M
Cash from Financing+	9.98M	34.93M	269.28M	181.49M	655K	195.88M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	-20K	-1.09M	-3.82M	0	25.74M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-1.33M	-6.18M	-38.23M	-147.92M	-174.14M	-130.16M
FCF Margin %	-	-1.19%	-	-	-	-43.63%
FCF Growth %	-	-3.63%	-5.18%	-2.87%	-0.18%	0.25%
FCF per Share	-0.01	-0.06	-0.40	-1.52	-1.91	-1.10
FCF Conversion (FCF/Net Income)	0.53x	1.63x	0.21x	1.08x	0.83x	0.63x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	141K	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-182.07%	-19.56%	-121.13%	-43.83%	-88.19%	-136.88%
Return on Invested Capital (ROIC)	-	-	-207.57%	-78.77%	-117.01%	-260.47%
Gross Margin	-	42.8%	-	-	-	100%
Net Margin	-	-65.45%	-	-	-	-6566.61%
Debt / Equity	-	-	0.04x	0.09x	0.10x	0.27x
FCF Conversion	0.53x	1.63x	0.21x	1.08x	0.83x	0.63x
Revenue Growth	-	-	-100%	-	-	-

Revenue by Segment

	2024
Reportable	2.98M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Prime Medicine, Inc. (PRME) reported $6.0M in revenue for fiscal year 2024.

Prime Medicine, Inc. (PRME) grew revenue by 0.0% over the past year. Growth has been modest.

Prime Medicine, Inc. (PRME) reported a net loss of $197.3M for fiscal year 2024.

Dividend & Returns

Prime Medicine, Inc. (PRME) has a return on equity (ROE) of -136.9%. Negative ROE indicates the company is unprofitable.

Prime Medicine, Inc. (PRME) had negative free cash flow of $115.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener